Items Tagged ‘CATNON trial’

June 7th, 2016

Temodar® After Radiation Improves Survival in Anaplastic Gliomas


The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Anaplastic gliomas are a type of brain […]

View full entry

Tags: 2016, Anaplastic gliomas, asco, Brain Cancer, CATNON trial, General Brain Cancer, News, radiation therapy, Temodar, temozolomide